nodes	percent_of_prediction	percent_of_DWPC	metapath
Pramipexole—SLC22A2—Cytarabine—lymphatic system cancer	0.279	0.535	CbGbCtD
Pramipexole—SLC22A1—Cytarabine—lymphatic system cancer	0.242	0.465	CbGbCtD
Pramipexole—Pulmonary oedema—Methotrexate—lymphatic system cancer	0.000402	0.000838	CcSEcCtD
Pramipexole—Confusional state—Bleomycin—lymphatic system cancer	0.000401	0.000838	CcSEcCtD
Pramipexole—Vision blurred—Carmustine—lymphatic system cancer	0.000401	0.000838	CcSEcCtD
Pramipexole—Hypersensitivity—Fludarabine—lymphatic system cancer	0.0004	0.000835	CcSEcCtD
Pramipexole—Tremor—Carmustine—lymphatic system cancer	0.000399	0.000833	CcSEcCtD
Pramipexole—Oedema—Bleomycin—lymphatic system cancer	0.000398	0.000831	CcSEcCtD
Pramipexole—Erythema—Mitoxantrone—lymphatic system cancer	0.000396	0.000826	CcSEcCtD
Pramipexole—Infection—Bleomycin—lymphatic system cancer	0.000396	0.000826	CcSEcCtD
Pramipexole—Anaemia—Carmustine—lymphatic system cancer	0.000394	0.000822	CcSEcCtD
Pramipexole—Back pain—Vincristine—lymphatic system cancer	0.000393	0.000821	CcSEcCtD
Pramipexole—Vomiting—Teniposide—lymphatic system cancer	0.000393	0.00082	CcSEcCtD
Pramipexole—Sepsis—Methotrexate—lymphatic system cancer	0.000392	0.000817	CcSEcCtD
Pramipexole—Agitation—Carmustine—lymphatic system cancer	0.000391	0.000817	CcSEcCtD
Pramipexole—Thrombocytopenia—Bleomycin—lymphatic system cancer	0.00039	0.000814	CcSEcCtD
Pramipexole—Asthenia—Fludarabine—lymphatic system cancer	0.00039	0.000813	CcSEcCtD
Pramipexole—Rash—Teniposide—lymphatic system cancer	0.00039	0.000813	CcSEcCtD
Pramipexole—Dermatitis—Teniposide—lymphatic system cancer	0.000389	0.000813	CcSEcCtD
Pramipexole—Dysgeusia—Mitoxantrone—lymphatic system cancer	0.000388	0.000809	CcSEcCtD
Pramipexole—Headache—Teniposide—lymphatic system cancer	0.000387	0.000808	CcSEcCtD
Pramipexole—Pruritus—Fludarabine—lymphatic system cancer	0.000384	0.000802	CcSEcCtD
Pramipexole—Lymphadenopathy—Methotrexate—lymphatic system cancer	0.000384	0.000801	CcSEcCtD
Pramipexole—Back pain—Mitoxantrone—lymphatic system cancer	0.000383	0.000799	CcSEcCtD
Pramipexole—Leukopenia—Carmustine—lymphatic system cancer	0.000381	0.000796	CcSEcCtD
Pramipexole—Anorexia—Bleomycin—lymphatic system cancer	0.000379	0.000792	CcSEcCtD
Pramipexole—Thrombophlebitis—Methotrexate—lymphatic system cancer	0.000378	0.00079	CcSEcCtD
Pramipexole—Diabetes mellitus—Methotrexate—lymphatic system cancer	0.000377	0.000786	CcSEcCtD
Pramipexole—Anaemia—Vincristine—lymphatic system cancer	0.000376	0.000784	CcSEcCtD
Pramipexole—Agitation—Vincristine—lymphatic system cancer	0.000374	0.00078	CcSEcCtD
Pramipexole—Vision blurred—Mitoxantrone—lymphatic system cancer	0.000373	0.000779	CcSEcCtD
Pramipexole—Hypotension—Bleomycin—lymphatic system cancer	0.000372	0.000777	CcSEcCtD
Pramipexole—Diarrhoea—Fludarabine—lymphatic system cancer	0.000372	0.000776	CcSEcCtD
Pramipexole—Convulsion—Carmustine—lymphatic system cancer	0.000369	0.00077	CcSEcCtD
Pramipexole—Hypertension—Carmustine—lymphatic system cancer	0.000368	0.000768	CcSEcCtD
Pramipexole—Ill-defined disorder—Mitoxantrone—lymphatic system cancer	0.000367	0.000767	CcSEcCtD
Pramipexole—Nausea—Teniposide—lymphatic system cancer	0.000367	0.000766	CcSEcCtD
Pramipexole—Anaemia—Mitoxantrone—lymphatic system cancer	0.000366	0.000764	CcSEcCtD
Pramipexole—Vertigo—Vincristine—lymphatic system cancer	0.000365	0.000762	CcSEcCtD
Pramipexole—Leukopenia—Vincristine—lymphatic system cancer	0.000364	0.00076	CcSEcCtD
Pramipexole—Musculoskeletal discomfort—Bleomycin—lymphatic system cancer	0.000363	0.000757	CcSEcCtD
Pramipexole—Chest pain—Carmustine—lymphatic system cancer	0.000363	0.000757	CcSEcCtD
Pramipexole—Myalgia—Carmustine—lymphatic system cancer	0.000363	0.000757	CcSEcCtD
Pramipexole—Anxiety—Carmustine—lymphatic system cancer	0.000361	0.000754	CcSEcCtD
Pramipexole—Paraesthesia—Bleomycin—lymphatic system cancer	0.000357	0.000746	CcSEcCtD
Pramipexole—Malaise—Mitoxantrone—lymphatic system cancer	0.000357	0.000745	CcSEcCtD
Pramipexole—Dyspnoea—Bleomycin—lymphatic system cancer	0.000355	0.000741	CcSEcCtD
Pramipexole—Leukopenia—Mitoxantrone—lymphatic system cancer	0.000354	0.00074	CcSEcCtD
Pramipexole—Convulsion—Vincristine—lymphatic system cancer	0.000352	0.000735	CcSEcCtD
Pramipexole—Hypertension—Vincristine—lymphatic system cancer	0.000351	0.000733	CcSEcCtD
Pramipexole—Confusional state—Carmustine—lymphatic system cancer	0.00035	0.000732	CcSEcCtD
Pramipexole—Oedema—Carmustine—lymphatic system cancer	0.000348	0.000726	CcSEcCtD
Pramipexole—Decreased appetite—Bleomycin—lymphatic system cancer	0.000346	0.000723	CcSEcCtD
Pramipexole—Myalgia—Vincristine—lymphatic system cancer	0.000346	0.000722	CcSEcCtD
Pramipexole—Visual disturbance—Methotrexate—lymphatic system cancer	0.000346	0.000722	CcSEcCtD
Pramipexole—Cough—Mitoxantrone—lymphatic system cancer	0.000345	0.000721	CcSEcCtD
Pramipexole—Infection—Carmustine—lymphatic system cancer	0.000345	0.000721	CcSEcCtD
Pramipexole—Vomiting—Fludarabine—lymphatic system cancer	0.000345	0.000721	CcSEcCtD
Pramipexole—Convulsion—Mitoxantrone—lymphatic system cancer	0.000343	0.000716	CcSEcCtD
Pramipexole—Rash—Fludarabine—lymphatic system cancer	0.000342	0.000715	CcSEcCtD
Pramipexole—Dermatitis—Fludarabine—lymphatic system cancer	0.000342	0.000714	CcSEcCtD
Pramipexole—Hypertension—Mitoxantrone—lymphatic system cancer	0.000342	0.000714	CcSEcCtD
Pramipexole—Pain—Bleomycin—lymphatic system cancer	0.00034	0.000711	CcSEcCtD
Pramipexole—Thrombocytopenia—Carmustine—lymphatic system cancer	0.00034	0.00071	CcSEcCtD
Pramipexole—Headache—Fludarabine—lymphatic system cancer	0.00034	0.00071	CcSEcCtD
Pramipexole—Tachycardia—Carmustine—lymphatic system cancer	0.000339	0.000708	CcSEcCtD
Pramipexole—Arthralgia—Mitoxantrone—lymphatic system cancer	0.000337	0.000704	CcSEcCtD
Pramipexole—Chest pain—Mitoxantrone—lymphatic system cancer	0.000337	0.000704	CcSEcCtD
Pramipexole—Myalgia—Mitoxantrone—lymphatic system cancer	0.000337	0.000704	CcSEcCtD
Pramipexole—Anxiety—Mitoxantrone—lymphatic system cancer	0.000336	0.000701	CcSEcCtD
Pramipexole—Lethargy—Methotrexate—lymphatic system cancer	0.000334	0.000698	CcSEcCtD
Pramipexole—Discomfort—Mitoxantrone—lymphatic system cancer	0.000333	0.000695	CcSEcCtD
Pramipexole—Oedema—Vincristine—lymphatic system cancer	0.000332	0.000693	CcSEcCtD
Pramipexole—Anorexia—Carmustine—lymphatic system cancer	0.000331	0.000692	CcSEcCtD
Pramipexole—Infection—Vincristine—lymphatic system cancer	0.00033	0.000688	CcSEcCtD
Pramipexole—Feeling abnormal—Bleomycin—lymphatic system cancer	0.000328	0.000685	CcSEcCtD
Pramipexole—Osteoarthritis—Methotrexate—lymphatic system cancer	0.000328	0.000684	CcSEcCtD
Pramipexole—Confusional state—Mitoxantrone—lymphatic system cancer	0.000326	0.00068	CcSEcCtD
Pramipexole—Nervous system disorder—Vincristine—lymphatic system cancer	0.000325	0.000679	CcSEcCtD
Pramipexole—Thrombocytopenia—Vincristine—lymphatic system cancer	0.000325	0.000678	CcSEcCtD
Pramipexole—Hypotension—Carmustine—lymphatic system cancer	0.000325	0.000678	CcSEcCtD
Pramipexole—Oedema—Mitoxantrone—lymphatic system cancer	0.000323	0.000675	CcSEcCtD
Pramipexole—Nausea—Fludarabine—lymphatic system cancer	0.000323	0.000673	CcSEcCtD
Pramipexole—Infection—Mitoxantrone—lymphatic system cancer	0.000321	0.00067	CcSEcCtD
Pramipexole—Hyperhidrosis—Vincristine—lymphatic system cancer	0.000321	0.00067	CcSEcCtD
Pramipexole—Shock—Mitoxantrone—lymphatic system cancer	0.000318	0.000664	CcSEcCtD
Pramipexole—Musculoskeletal discomfort—Carmustine—lymphatic system cancer	0.000317	0.000661	CcSEcCtD
Pramipexole—Thrombocytopenia—Mitoxantrone—lymphatic system cancer	0.000316	0.00066	CcSEcCtD
Pramipexole—Urticaria—Bleomycin—lymphatic system cancer	0.000316	0.00066	CcSEcCtD
Pramipexole—Anorexia—Vincristine—lymphatic system cancer	0.000316	0.00066	CcSEcCtD
Pramipexole—Tachycardia—Mitoxantrone—lymphatic system cancer	0.000315	0.000658	CcSEcCtD
Pramipexole—Body temperature increased—Bleomycin—lymphatic system cancer	0.000315	0.000657	CcSEcCtD
Pramipexole—Insomnia—Carmustine—lymphatic system cancer	0.000314	0.000656	CcSEcCtD
Pramipexole—Skin disorder—Mitoxantrone—lymphatic system cancer	0.000314	0.000655	CcSEcCtD
Pramipexole—Irritability—Methotrexate—lymphatic system cancer	0.000313	0.000653	CcSEcCtD
Pramipexole—Hyperhidrosis—Mitoxantrone—lymphatic system cancer	0.000312	0.000652	CcSEcCtD
Pramipexole—Paraesthesia—Carmustine—lymphatic system cancer	0.000312	0.000652	CcSEcCtD
Pramipexole—Mood swings—Methotrexate—lymphatic system cancer	0.00031	0.000648	CcSEcCtD
Pramipexole—Hypotension—Vincristine—lymphatic system cancer	0.00031	0.000647	CcSEcCtD
Pramipexole—Dyspnoea—Carmustine—lymphatic system cancer	0.00031	0.000647	CcSEcCtD
Pramipexole—Somnolence—Carmustine—lymphatic system cancer	0.000309	0.000645	CcSEcCtD
Pramipexole—Anorexia—Mitoxantrone—lymphatic system cancer	0.000308	0.000643	CcSEcCtD
Pramipexole—Ataxia—Methotrexate—lymphatic system cancer	0.000308	0.000643	CcSEcCtD
Pramipexole—Musculoskeletal discomfort—Vincristine—lymphatic system cancer	0.000302	0.000631	CcSEcCtD
Pramipexole—Decreased appetite—Carmustine—lymphatic system cancer	0.000302	0.000631	CcSEcCtD
Pramipexole—Hypotension—Mitoxantrone—lymphatic system cancer	0.000302	0.00063	CcSEcCtD
Pramipexole—Insomnia—Vincristine—lymphatic system cancer	0.0003	0.000626	CcSEcCtD
Pramipexole—Gastrointestinal disorder—Carmustine—lymphatic system cancer	0.0003	0.000626	CcSEcCtD
Pramipexole—Paraesthesia—Vincristine—lymphatic system cancer	0.000298	0.000622	CcSEcCtD
Pramipexole—Pain—Carmustine—lymphatic system cancer	0.000297	0.00062	CcSEcCtD
Pramipexole—Constipation—Carmustine—lymphatic system cancer	0.000297	0.00062	CcSEcCtD
Pramipexole—Breast disorder—Methotrexate—lymphatic system cancer	0.000296	0.000618	CcSEcCtD
Pramipexole—Musculoskeletal discomfort—Mitoxantrone—lymphatic system cancer	0.000294	0.000615	CcSEcCtD
Pramipexole—Hypersensitivity—Bleomycin—lymphatic system cancer	0.000293	0.000612	CcSEcCtD
Pramipexole—Paraesthesia—Mitoxantrone—lymphatic system cancer	0.00029	0.000606	CcSEcCtD
Pramipexole—Decreased appetite—Vincristine—lymphatic system cancer	0.000288	0.000602	CcSEcCtD
Pramipexole—Dyspnoea—Mitoxantrone—lymphatic system cancer	0.000288	0.000601	CcSEcCtD
Pramipexole—Somnolence—Mitoxantrone—lymphatic system cancer	0.000287	0.0006	CcSEcCtD
Pramipexole—Gastrointestinal disorder—Vincristine—lymphatic system cancer	0.000286	0.000598	CcSEcCtD
Pramipexole—Feeling abnormal—Carmustine—lymphatic system cancer	0.000286	0.000598	CcSEcCtD
Pramipexole—Fatigue—Vincristine—lymphatic system cancer	0.000286	0.000597	CcSEcCtD
Pramipexole—Asthenia—Bleomycin—lymphatic system cancer	0.000286	0.000596	CcSEcCtD
Pramipexole—Dyspepsia—Mitoxantrone—lymphatic system cancer	0.000284	0.000594	CcSEcCtD
Pramipexole—Gastrointestinal pain—Carmustine—lymphatic system cancer	0.000284	0.000593	CcSEcCtD
Pramipexole—Pain—Vincristine—lymphatic system cancer	0.000284	0.000592	CcSEcCtD
Pramipexole—Constipation—Vincristine—lymphatic system cancer	0.000284	0.000592	CcSEcCtD
Pramipexole—Asthma—Methotrexate—lymphatic system cancer	0.000283	0.000591	CcSEcCtD
Pramipexole—Pruritus—Bleomycin—lymphatic system cancer	0.000282	0.000588	CcSEcCtD
Pramipexole—Decreased appetite—Mitoxantrone—lymphatic system cancer	0.000281	0.000586	CcSEcCtD
Pramipexole—Fatigue—Mitoxantrone—lymphatic system cancer	0.000279	0.000582	CcSEcCtD
Pramipexole—Pancreatitis—Methotrexate—lymphatic system cancer	0.000278	0.000579	CcSEcCtD
Pramipexole—Constipation—Mitoxantrone—lymphatic system cancer	0.000276	0.000577	CcSEcCtD
Pramipexole—Pain—Mitoxantrone—lymphatic system cancer	0.000276	0.000577	CcSEcCtD
Pramipexole—Abdominal pain—Carmustine—lymphatic system cancer	0.000275	0.000574	CcSEcCtD
Pramipexole—Body temperature increased—Carmustine—lymphatic system cancer	0.000275	0.000574	CcSEcCtD
Pramipexole—Abdominal discomfort—Methotrexate—lymphatic system cancer	0.000271	0.000567	CcSEcCtD
Pramipexole—Gastrointestinal pain—Vincristine—lymphatic system cancer	0.000271	0.000566	CcSEcCtD
Pramipexole—Feeling abnormal—Mitoxantrone—lymphatic system cancer	0.000266	0.000556	CcSEcCtD
Pramipexole—Dysuria—Methotrexate—lymphatic system cancer	0.000265	0.000553	CcSEcCtD
Pramipexole—Gastrointestinal pain—Mitoxantrone—lymphatic system cancer	0.000264	0.000552	CcSEcCtD
Pramipexole—Upper respiratory tract infection—Methotrexate—lymphatic system cancer	0.000263	0.000549	CcSEcCtD
Pramipexole—Body temperature increased—Vincristine—lymphatic system cancer	0.000262	0.000548	CcSEcCtD
Pramipexole—Abdominal pain—Vincristine—lymphatic system cancer	0.000262	0.000548	CcSEcCtD
Pramipexole—Erectile dysfunction—Methotrexate—lymphatic system cancer	0.000261	0.000544	CcSEcCtD
Pramipexole—Photosensitivity reaction—Methotrexate—lymphatic system cancer	0.000258	0.000539	CcSEcCtD
Pramipexole—Urticaria—Mitoxantrone—lymphatic system cancer	0.000257	0.000536	CcSEcCtD
Pramipexole—Hypersensitivity—Carmustine—lymphatic system cancer	0.000256	0.000535	CcSEcCtD
Pramipexole—Abdominal pain—Mitoxantrone—lymphatic system cancer	0.000255	0.000533	CcSEcCtD
Pramipexole—Body temperature increased—Mitoxantrone—lymphatic system cancer	0.000255	0.000533	CcSEcCtD
Pramipexole—Pneumonia—Methotrexate—lymphatic system cancer	0.000254	0.00053	CcSEcCtD
Pramipexole—Vomiting—Bleomycin—lymphatic system cancer	0.000253	0.000528	CcSEcCtD
Pramipexole—Infestation—Methotrexate—lymphatic system cancer	0.000252	0.000527	CcSEcCtD
Pramipexole—Drowsiness—Methotrexate—lymphatic system cancer	0.000252	0.000527	CcSEcCtD
Pramipexole—Infestation NOS—Methotrexate—lymphatic system cancer	0.000252	0.000527	CcSEcCtD
Pramipexole—Depression—Methotrexate—lymphatic system cancer	0.000252	0.000525	CcSEcCtD
Pramipexole—Rash—Bleomycin—lymphatic system cancer	0.000251	0.000524	CcSEcCtD
Pramipexole—Dermatitis—Bleomycin—lymphatic system cancer	0.000251	0.000524	CcSEcCtD
Pramipexole—Asthenia—Carmustine—lymphatic system cancer	0.000249	0.000521	CcSEcCtD
Pramipexole—Renal failure—Methotrexate—lymphatic system cancer	0.000248	0.000518	CcSEcCtD
Pramipexole—Conjunctivitis—Methotrexate—lymphatic system cancer	0.000245	0.000512	CcSEcCtD
Pramipexole—Hypersensitivity—Vincristine—lymphatic system cancer	0.000244	0.00051	CcSEcCtD
Pramipexole—Sweating—Methotrexate—lymphatic system cancer	0.000242	0.000505	CcSEcCtD
Pramipexole—Haematuria—Methotrexate—lymphatic system cancer	0.000241	0.000502	CcSEcCtD
Pramipexole—Hepatobiliary disease—Methotrexate—lymphatic system cancer	0.000239	0.000498	CcSEcCtD
Pramipexole—Epistaxis—Methotrexate—lymphatic system cancer	0.000238	0.000497	CcSEcCtD
Pramipexole—Hypersensitivity—Mitoxantrone—lymphatic system cancer	0.000238	0.000497	CcSEcCtD
Pramipexole—Asthenia—Vincristine—lymphatic system cancer	0.000238	0.000497	CcSEcCtD
Pramipexole—Diarrhoea—Carmustine—lymphatic system cancer	0.000238	0.000496	CcSEcCtD
Pramipexole—Nausea—Bleomycin—lymphatic system cancer	0.000236	0.000494	CcSEcCtD
Pramipexole—Asthenia—Mitoxantrone—lymphatic system cancer	0.000232	0.000484	CcSEcCtD
Pramipexole—Dizziness—Carmustine—lymphatic system cancer	0.00023	0.00048	CcSEcCtD
Pramipexole—Diarrhoea—Vincristine—lymphatic system cancer	0.000227	0.000474	CcSEcCtD
Pramipexole—Pharyngitis—Methotrexate—lymphatic system cancer	0.000225	0.000469	CcSEcCtD
Pramipexole—Urinary tract disorder—Methotrexate—lymphatic system cancer	0.000224	0.000467	CcSEcCtD
Pramipexole—Urethral disorder—Methotrexate—lymphatic system cancer	0.000222	0.000464	CcSEcCtD
Pramipexole—Diarrhoea—Mitoxantrone—lymphatic system cancer	0.000221	0.000462	CcSEcCtD
Pramipexole—Vomiting—Carmustine—lymphatic system cancer	0.000221	0.000461	CcSEcCtD
Pramipexole—Dizziness—Vincristine—lymphatic system cancer	0.000219	0.000458	CcSEcCtD
Pramipexole—Rash—Carmustine—lymphatic system cancer	0.000219	0.000457	CcSEcCtD
Pramipexole—Dermatitis—Carmustine—lymphatic system cancer	0.000219	0.000457	CcSEcCtD
Pramipexole—Visual impairment—Methotrexate—lymphatic system cancer	0.000218	0.000456	CcSEcCtD
Pramipexole—Headache—Carmustine—lymphatic system cancer	0.000218	0.000455	CcSEcCtD
Pramipexole—Eye disorder—Methotrexate—lymphatic system cancer	0.000212	0.000442	CcSEcCtD
Pramipexole—Tinnitus—Methotrexate—lymphatic system cancer	0.000211	0.000441	CcSEcCtD
Pramipexole—Vomiting—Vincristine—lymphatic system cancer	0.000211	0.00044	CcSEcCtD
Pramipexole—Cardiac disorder—Methotrexate—lymphatic system cancer	0.00021	0.000439	CcSEcCtD
Pramipexole—Rash—Vincristine—lymphatic system cancer	0.000209	0.000437	CcSEcCtD
Pramipexole—Dermatitis—Vincristine—lymphatic system cancer	0.000209	0.000436	CcSEcCtD
Pramipexole—Headache—Vincristine—lymphatic system cancer	0.000208	0.000434	CcSEcCtD
Pramipexole—Nausea—Carmustine—lymphatic system cancer	0.000206	0.000431	CcSEcCtD
Pramipexole—Angiopathy—Methotrexate—lymphatic system cancer	0.000206	0.000429	CcSEcCtD
Pramipexole—Vomiting—Mitoxantrone—lymphatic system cancer	0.000205	0.000429	CcSEcCtD
Pramipexole—Immune system disorder—Methotrexate—lymphatic system cancer	0.000205	0.000427	CcSEcCtD
Pramipexole—Mediastinal disorder—Methotrexate—lymphatic system cancer	0.000204	0.000426	CcSEcCtD
Pramipexole—Rash—Mitoxantrone—lymphatic system cancer	0.000204	0.000425	CcSEcCtD
Pramipexole—Dermatitis—Mitoxantrone—lymphatic system cancer	0.000204	0.000425	CcSEcCtD
Pramipexole—Chills—Methotrexate—lymphatic system cancer	0.000203	0.000424	CcSEcCtD
Pramipexole—Headache—Mitoxantrone—lymphatic system cancer	0.000202	0.000423	CcSEcCtD
Pramipexole—Alopecia—Methotrexate—lymphatic system cancer	0.0002	0.000418	CcSEcCtD
Pramipexole—Mental disorder—Methotrexate—lymphatic system cancer	0.000198	0.000414	CcSEcCtD
Pramipexole—Malnutrition—Methotrexate—lymphatic system cancer	0.000197	0.000412	CcSEcCtD
Pramipexole—Erythema—Methotrexate—lymphatic system cancer	0.000197	0.000412	CcSEcCtD
Pramipexole—Nausea—Vincristine—lymphatic system cancer	0.000197	0.000411	CcSEcCtD
Pramipexole—Dysgeusia—Methotrexate—lymphatic system cancer	0.000193	0.000403	CcSEcCtD
Pramipexole—Nausea—Mitoxantrone—lymphatic system cancer	0.000192	0.000401	CcSEcCtD
Pramipexole—Back pain—Methotrexate—lymphatic system cancer	0.000191	0.000398	CcSEcCtD
Pramipexole—Vision blurred—Methotrexate—lymphatic system cancer	0.000186	0.000388	CcSEcCtD
Pramipexole—Ill-defined disorder—Methotrexate—lymphatic system cancer	0.000183	0.000382	CcSEcCtD
Pramipexole—Anaemia—Methotrexate—lymphatic system cancer	0.000182	0.000381	CcSEcCtD
Pramipexole—Malaise—Methotrexate—lymphatic system cancer	0.000178	0.000371	CcSEcCtD
Pramipexole—Vertigo—Methotrexate—lymphatic system cancer	0.000177	0.00037	CcSEcCtD
Pramipexole—Leukopenia—Methotrexate—lymphatic system cancer	0.000177	0.000369	CcSEcCtD
Pramipexole—Cough—Methotrexate—lymphatic system cancer	0.000172	0.000359	CcSEcCtD
Pramipexole—Convulsion—Methotrexate—lymphatic system cancer	0.000171	0.000357	CcSEcCtD
Pramipexole—Arthralgia—Methotrexate—lymphatic system cancer	0.000168	0.000351	CcSEcCtD
Pramipexole—Myalgia—Methotrexate—lymphatic system cancer	0.000168	0.000351	CcSEcCtD
Pramipexole—Chest pain—Methotrexate—lymphatic system cancer	0.000168	0.000351	CcSEcCtD
Pramipexole—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—lymphatic system cancer	0.000167	0.000348	CcSEcCtD
Pramipexole—Discomfort—Methotrexate—lymphatic system cancer	0.000166	0.000346	CcSEcCtD
Pramipexole—Confusional state—Methotrexate—lymphatic system cancer	0.000162	0.000339	CcSEcCtD
Pramipexole—Infection—Methotrexate—lymphatic system cancer	0.00016	0.000334	CcSEcCtD
Pramipexole—Nervous system disorder—Methotrexate—lymphatic system cancer	0.000158	0.00033	CcSEcCtD
Pramipexole—Thrombocytopenia—Methotrexate—lymphatic system cancer	0.000158	0.000329	CcSEcCtD
Pramipexole—Skin disorder—Methotrexate—lymphatic system cancer	0.000156	0.000326	CcSEcCtD
Pramipexole—Hyperhidrosis—Methotrexate—lymphatic system cancer	0.000156	0.000325	CcSEcCtD
Pramipexole—Anorexia—Methotrexate—lymphatic system cancer	0.000153	0.00032	CcSEcCtD
Pramipexole—Hypotension—Methotrexate—lymphatic system cancer	0.00015	0.000314	CcSEcCtD
Pramipexole—Musculoskeletal discomfort—Methotrexate—lymphatic system cancer	0.000147	0.000306	CcSEcCtD
Pramipexole—Insomnia—Methotrexate—lymphatic system cancer	0.000146	0.000304	CcSEcCtD
Pramipexole—Paraesthesia—Methotrexate—lymphatic system cancer	0.000145	0.000302	CcSEcCtD
Pramipexole—Dyspnoea—Methotrexate—lymphatic system cancer	0.000144	0.0003	CcSEcCtD
Pramipexole—Somnolence—Methotrexate—lymphatic system cancer	0.000143	0.000299	CcSEcCtD
Pramipexole—Dyspepsia—Methotrexate—lymphatic system cancer	0.000142	0.000296	CcSEcCtD
Pramipexole—Decreased appetite—Methotrexate—lymphatic system cancer	0.00014	0.000292	CcSEcCtD
Pramipexole—Gastrointestinal disorder—Methotrexate—lymphatic system cancer	0.000139	0.00029	CcSEcCtD
Pramipexole—Fatigue—Methotrexate—lymphatic system cancer	0.000139	0.00029	CcSEcCtD
Pramipexole—Pain—Methotrexate—lymphatic system cancer	0.000138	0.000287	CcSEcCtD
Pramipexole—Feeling abnormal—Methotrexate—lymphatic system cancer	0.000133	0.000277	CcSEcCtD
Pramipexole—Gastrointestinal pain—Methotrexate—lymphatic system cancer	0.000132	0.000275	CcSEcCtD
Pramipexole—Urticaria—Methotrexate—lymphatic system cancer	0.000128	0.000267	CcSEcCtD
Pramipexole—Abdominal pain—Methotrexate—lymphatic system cancer	0.000127	0.000266	CcSEcCtD
Pramipexole—Body temperature increased—Methotrexate—lymphatic system cancer	0.000127	0.000266	CcSEcCtD
Pramipexole—Hypersensitivity—Methotrexate—lymphatic system cancer	0.000119	0.000248	CcSEcCtD
Pramipexole—Asthenia—Methotrexate—lymphatic system cancer	0.000115	0.000241	CcSEcCtD
Pramipexole—Pruritus—Methotrexate—lymphatic system cancer	0.000114	0.000238	CcSEcCtD
Pramipexole—Diarrhoea—Methotrexate—lymphatic system cancer	0.00011	0.00023	CcSEcCtD
Pramipexole—Dizziness—Methotrexate—lymphatic system cancer	0.000106	0.000222	CcSEcCtD
Pramipexole—Vomiting—Methotrexate—lymphatic system cancer	0.000102	0.000214	CcSEcCtD
Pramipexole—Rash—Methotrexate—lymphatic system cancer	0.000101	0.000212	CcSEcCtD
Pramipexole—Dermatitis—Methotrexate—lymphatic system cancer	0.000101	0.000212	CcSEcCtD
Pramipexole—Headache—Methotrexate—lymphatic system cancer	0.000101	0.000211	CcSEcCtD
Pramipexole—Nausea—Methotrexate—lymphatic system cancer	9.56e-05	0.0002	CcSEcCtD
